Fred Alger Management’s BridgeBio Pharma BBIO Stock Holding History

Fred Alger Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Sell	22,170 -105,049	-83%	-$7.36M	0.01%	330
2026 Q1	$9.45M	Sell	127,219 -76,877	-38%	-$5.57M	0.04%	171
2025 Q4	$15.6M	Buy	204,096 +6,731	+3%	+$442K	0.06%	135
2025 Q3	$10.3M	Buy	197,365 +173,566	+729%	+$8.47M	0.04%	180
2025 Q2	$1.03M	Sell	23,799 -4,600	-16%	-$167K	﹤0.01%	355
2025 Q1	$982K	Buy	+28,399	New	+$958K	0.01%	331
2024 Q1	–	Sell	-122,797	Closed	-$4.96M	–	449
2023 Q4	$4.96M	Sell	122,797 -8,826	-7%	-$265K	0.03%	246
2023 Q3	$3.47M	Buy	+131,623	New	+$3.74M	0.02%	280

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Fred Alger Management's BBIO Position: Q2 2026 in Review

Fred Alger Management reduced its BridgeBio Pharma (BBIO) stake by 83% in Q2 2026, selling an estimated $7.36M and leaving 22,170 shares worth $1.65M. The position accounts for 0.01% of the portfolio, ranked #330.

Fred Alger Management first reported a position in BBIO in Q3 2023 and has held it in 8 quarters since. The position peaked at $15.6M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Fred Alger Management held 22,170 shares of BridgeBio Pharma worth $1.65M as of Q2 2026.
Fred Alger Management sold 105,049 BridgeBio Pharma shares in Q2 2026, an estimated $7.36M.
BridgeBio Pharma made up 0.01% of Fred Alger Management's portfolio in Q2 2026, its #330 holding.
Fred Alger Management first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 8 quarters since.
Fred Alger Management's BridgeBio Pharma position peaked at $15.6M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.